Skip to main content
Erschienen in: Breast Cancer Research and Treatment 1/2010

01.08.2010 | Preclinical study

Prognostic impact of ALDH1 in breast cancer: a story of stem cells and tumor microenvironment

verfasst von: Erika Resetkova, Jorge S. Reis-Filho, Rohit K. Jain, Rutika Mehta, Mangesh A. Thorat, Harikrishna Nakshatri, Sunil Badve

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 1/2010

Einloggen, um Zugang zu erhalten

Abstract

The concept of cancer cells being hierarchically organized and arising from their own progenitor stem cells will have important implications on cancer therapy. If this hypothesis were to be true then the paucity of estrogen receptors in stem cells as well as their inherent drug resistance mechanisms pose a challenge to current targeted therapies. In this study, we sought to examine the prognostic relevance of ALDH1, a putative cancer stem cell marker, by immunohistochemistry. The four cohorts analyzed included an adjuvantly treated series of 245 invasive cancers, a neoadjuvantly treated series of 34 cases, and two series of 58 and 40 triple negative cases, respectively. Both tumor cell and stromal expression for ALDH1 was evaluated, where possible. Tumor cell ALDH1 expression significantly correlated only with basal-like and HER2 tumor types in the adjuvant series and tumor grade in the neoadjuvant cohort. No significant enrichment for ALDH1 positive cells was observed in the postneoadjuvant therapy specimens compared to pretreatment samples. On the other hand, high degree of stromal expression was significantly associated with best disease-free survival as well as a trend for overall survival. The association of stromal expression was confirmed in an independent cohort of triple negative cases. The novel finding is that tumor microenvironment may play a significant role in determining the prognostic impact of stem/progenitor cells in human breast tumors.
Literatur
1.
Zurück zum Zitat Cohnheim J (1867) Ueber entzundung und eiterung. Path Anat Physiol Klin Med 40:1–79 Cohnheim J (1867) Ueber entzundung und eiterung. Path Anat Physiol Klin Med 40:1–79
2.
Zurück zum Zitat Nakshatri H, Srour EF, Badve S (2009) Breast cancer stem cells and intrinsic subtypes: controversies rage on. Curr Stem Cell Res Ther 4:50–60CrossRefPubMed Nakshatri H, Srour EF, Badve S (2009) Breast cancer stem cells and intrinsic subtypes: controversies rage on. Curr Stem Cell Res Ther 4:50–60CrossRefPubMed
4.
Zurück zum Zitat Visvader JE, Lindeman GJ (2008) Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 8:755–768CrossRefPubMed Visvader JE, Lindeman GJ (2008) Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 8:755–768CrossRefPubMed
5.
Zurück zum Zitat Hill RP, Perris R (2007) “Destemming” cancer stem cells. J Natl Cancer Inst 99:1435–1440CrossRefPubMed Hill RP, Perris R (2007) “Destemming” cancer stem cells. J Natl Cancer Inst 99:1435–1440CrossRefPubMed
6.
Zurück zum Zitat Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CH, Jones DL, Visvader J, Weissman IL, Wahl GM (2006) Cancer stem cells—perspectives on current status and future directions: AACR workshop on cancer stem cells. Cancer Res 66:9339–9344CrossRefPubMed Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CH, Jones DL, Visvader J, Weissman IL, Wahl GM (2006) Cancer stem cells—perspectives on current status and future directions: AACR workshop on cancer stem cells. Cancer Res 66:9339–9344CrossRefPubMed
7.
Zurück zum Zitat Kakarala M, Wicha MS (2008) Implications of the cancer stem-cell hypothesis for breast cancer prevention and therapy. J Clin Oncol 26:2813–2820CrossRefPubMed Kakarala M, Wicha MS (2008) Implications of the cancer stem-cell hypothesis for breast cancer prevention and therapy. J Clin Oncol 26:2813–2820CrossRefPubMed
8.
Zurück zum Zitat Morrison BJ, Schmidt CW, Lakhani SR, Reynolds BA, Lopez JA (2008) Breast cancer stem cells: implications for therapy of breast cancer. Breast Cancer Res 10:210CrossRefPubMed Morrison BJ, Schmidt CW, Lakhani SR, Reynolds BA, Lopez JA (2008) Breast cancer stem cells: implications for therapy of breast cancer. Breast Cancer Res 10:210CrossRefPubMed
9.
Zurück zum Zitat Dontu G, Abdallah WM, Foley JM, Jackson KW, Clarke MF, Kawamura MJ, Wicha MS (2003) In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev 17:1253–1270CrossRefPubMed Dontu G, Abdallah WM, Foley JM, Jackson KW, Clarke MF, Kawamura MJ, Wicha MS (2003) In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev 17:1253–1270CrossRefPubMed
10.
Zurück zum Zitat Phillips TM, McBride WH, Pajonk F (2006) The response of cd24(−/low)/cd44+ breast cancer-initiating cells to radiation. J Natl Cancer Inst 98:1777–1785CrossRefPubMed Phillips TM, McBride WH, Pajonk F (2006) The response of cd24(−/low)/cd44+ breast cancer-initiating cells to radiation. J Natl Cancer Inst 98:1777–1785CrossRefPubMed
11.
Zurück zum Zitat Li X, Lewis MT, Huang J, Gutierrez C, Osborne CK, Wu MF, Hilsenbeck SG, Pavlick A, Zhang X, Chamness GC, Wong H, Rosen J, Chang JC (2008) Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 100:672–679CrossRefPubMed Li X, Lewis MT, Huang J, Gutierrez C, Osborne CK, Wu MF, Hilsenbeck SG, Pavlick A, Zhang X, Chamness GC, Wong H, Rosen J, Chang JC (2008) Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 100:672–679CrossRefPubMed
12.
Zurück zum Zitat O’Brien CS, Farnie G, Howell SJ, Clarke RB (2008) Are stem-like cells responsible for resistance to therapy in breast cancer? Breast Dis 29:83–89PubMed O’Brien CS, Farnie G, Howell SJ, Clarke RB (2008) Are stem-like cells responsible for resistance to therapy in breast cancer? Breast Dis 29:83–89PubMed
13.
Zurück zum Zitat Eyler CE, Rich JN (2008) Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis. J Clin Oncol 26:2839–2845CrossRefPubMed Eyler CE, Rich JN (2008) Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis. J Clin Oncol 26:2839–2845CrossRefPubMed
14.
Zurück zum Zitat Diehn M, Clarke MF (2006) Cancer stem cells and radiotherapy: new insights into tumor radioresistance. J Natl Cancer Inst 98:1755–1757CrossRefPubMed Diehn M, Clarke MF (2006) Cancer stem cells and radiotherapy: new insights into tumor radioresistance. J Natl Cancer Inst 98:1755–1757CrossRefPubMed
15.
Zurück zum Zitat Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100:3983–3988CrossRefPubMed Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100:3983–3988CrossRefPubMed
16.
Zurück zum Zitat Sheridan C, Kishimoto H, Fuchs RK, Mehrotra S, Bhat-Nakshatri P, Turner CH, Goulet R Jr, Badve S, Nakshatri H (2006) Cd44+/cd24− breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis. Breast Cancer Res 8:R59CrossRefPubMed Sheridan C, Kishimoto H, Fuchs RK, Mehrotra S, Bhat-Nakshatri P, Turner CH, Goulet R Jr, Badve S, Nakshatri H (2006) Cd44+/cd24− breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis. Breast Cancer Res 8:R59CrossRefPubMed
17.
Zurück zum Zitat Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, Campbell LL, Polyak K, Brisken C, Yang J, Weinberg RA (2008) The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133:704–715CrossRefPubMed Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, Campbell LL, Polyak K, Brisken C, Yang J, Weinberg RA (2008) The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133:704–715CrossRefPubMed
18.
Zurück zum Zitat Honeth G, Bendahl PO, Ringner M, Saal LH, Gruvberger-Saal SK, Lovgren K, Grabau D, Ferno M, Borg A, Hegardt C (2008) The cd44+/cd24− phenotype is enriched in basal-like breast tumors. Breast Cancer Res 10:R53CrossRefPubMed Honeth G, Bendahl PO, Ringner M, Saal LH, Gruvberger-Saal SK, Lovgren K, Grabau D, Ferno M, Borg A, Hegardt C (2008) The cd44+/cd24− phenotype is enriched in basal-like breast tumors. Breast Cancer Res 10:R53CrossRefPubMed
19.
Zurück zum Zitat Xiao Y, Ye Y, Yearsley K, Jones S, Barsky SH (2008) The lymphovascular embolus of inflammatory breast cancer expresses a stem cell-like phenotype. Am J Pathol 173:561–574CrossRefPubMed Xiao Y, Ye Y, Yearsley K, Jones S, Barsky SH (2008) The lymphovascular embolus of inflammatory breast cancer expresses a stem cell-like phenotype. Am J Pathol 173:561–574CrossRefPubMed
20.
Zurück zum Zitat Mylona E, Giannopoulou I, Fasomytakis E, Nomikos A, Magkou C, Bakarakos P, Nakopoulou L (2008) The clinicopathologic and prognostic significance of cd44+/cd24(−/low) and cd44−/cd24+ tumor cells in invasive breast carcinomas. Hum Pathol 39:1096–1102CrossRefPubMed Mylona E, Giannopoulou I, Fasomytakis E, Nomikos A, Magkou C, Bakarakos P, Nakopoulou L (2008) The clinicopathologic and prognostic significance of cd44+/cd24(−/low) and cd44−/cd24+ tumor cells in invasive breast carcinomas. Hum Pathol 39:1096–1102CrossRefPubMed
21.
Zurück zum Zitat Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, Jacquemier J, Viens P, Kleer CG, Liu S, Schott A, Hayes D, Birnbaum D, Wicha MS, Dontu G (2007) ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 1:555–567CrossRefPubMed Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, Jacquemier J, Viens P, Kleer CG, Liu S, Schott A, Hayes D, Birnbaum D, Wicha MS, Dontu G (2007) ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 1:555–567CrossRefPubMed
22.
Zurück zum Zitat Croker AK, Goodale D, Chu J, Postenka C, Hedley BD, Hess DA, Allan AL (2008) High aldehyde dehydrogenase and expression of cancer stem cell markers selects for breast cancer cells with enhanced malignant and metastatic ability. J Cell Mol Med. doi:10.1111/j.1582-4934.2008.00455.x Croker AK, Goodale D, Chu J, Postenka C, Hedley BD, Hess DA, Allan AL (2008) High aldehyde dehydrogenase and expression of cancer stem cell markers selects for breast cancer cells with enhanced malignant and metastatic ability. J Cell Mol Med. doi:10.​1111/​j.​1582-4934.​2008.​00455.​x
23.
Zurück zum Zitat Neumeister V, Agarwal S, Camp R, Rimm D (2009) In situ characterization of possible cancer stem cells in breast cancer by multiplexing ALDH1, CD44 and cytokeratin on tissue microarrays. Cancer Res 69:102CrossRef Neumeister V, Agarwal S, Camp R, Rimm D (2009) In situ characterization of possible cancer stem cells in breast cancer by multiplexing ALDH1, CD44 and cytokeratin on tissue microarrays. Cancer Res 69:102CrossRef
24.
Zurück zum Zitat Tanei T, Morimoto K, Shimazu K, Kim SJ, Tanji Y, Taguchi T, Tamaki Y, Noguchi S (2009) Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential paclitaxel and epirubicin-based chemotherapy for breast cancers. Clin Cancer Res 15:4234–4241CrossRefPubMed Tanei T, Morimoto K, Shimazu K, Kim SJ, Tanji Y, Taguchi T, Tamaki Y, Noguchi S (2009) Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential paclitaxel and epirubicin-based chemotherapy for breast cancers. Clin Cancer Res 15:4234–4241CrossRefPubMed
25.
Zurück zum Zitat Kunju LP, Toy K, Thomas D, Ding Y, Kleer CG (2009) Expression of the stem cell markers ALDH1 and EZH2 in triple negative invasive breast carcinomas. [Abstracts of the annual meeting of the united states and canadian academy of pathology. March 7–13, 2009. Boston, Massachusetts, USA]. Lab Invest 89(Suppl 1):52A Kunju LP, Toy K, Thomas D, Ding Y, Kleer CG (2009) Expression of the stem cell markers ALDH1 and EZH2 in triple negative invasive breast carcinomas. [Abstracts of the annual meeting of the united states and canadian academy of pathology. March 7–13, 2009. Boston, Massachusetts, USA]. Lab Invest 89(Suppl 1):52A
26.
Zurück zum Zitat Korkaya H, Paulson A, Iovino F, Wicha MS (2008) HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion. Oncogene 27:6120–6130CrossRefPubMed Korkaya H, Paulson A, Iovino F, Wicha MS (2008) HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion. Oncogene 27:6120–6130CrossRefPubMed
27.
Zurück zum Zitat Arriola E, Rodriguez-Pinilla SM, Lambros MB, Jones RL, James M, Savage K, Smith IE, Dowsett M, Reis-Filho JS (2007) Topoisomerase ii alpha amplification may predict benefit from adjuvant anthracyclines in HER2 positive early breast cancer. Breast Cancer Res Treat 106:181–189CrossRefPubMed Arriola E, Rodriguez-Pinilla SM, Lambros MB, Jones RL, James M, Savage K, Smith IE, Dowsett M, Reis-Filho JS (2007) Topoisomerase ii alpha amplification may predict benefit from adjuvant anthracyclines in HER2 positive early breast cancer. Breast Cancer Res Treat 106:181–189CrossRefPubMed
28.
Zurück zum Zitat Tan DS, Marchio C, Jones RL, Savage K, Smith IE, Dowsett M, Reis-Filho JS (2008) Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients. Breast Cancer Res Treat 111:27–44CrossRefPubMed Tan DS, Marchio C, Jones RL, Savage K, Smith IE, Dowsett M, Reis-Filho JS (2008) Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients. Breast Cancer Res Treat 111:27–44CrossRefPubMed
29.
Zurück zum Zitat Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, Hernandez-Boussard T, Livasy C, Cowan D, Dressler L, Akslen LA, Ragaz J, Gown AM, Gilks CB, van de Rijn M, Perou CM (2004) Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 10:5367–5374CrossRefPubMed Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, Hernandez-Boussard T, Livasy C, Cowan D, Dressler L, Akslen LA, Ragaz J, Gown AM, Gilks CB, van de Rijn M, Perou CM (2004) Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 10:5367–5374CrossRefPubMed
30.
Zurück zum Zitat Bhargava R, Beriwal S, McManus K, Dabbs D (2009) ALDH1 expression in human breast carcinoma. Cancer Res 69:5057CrossRef Bhargava R, Beriwal S, McManus K, Dabbs D (2009) ALDH1 expression in human breast carcinoma. Cancer Res 69:5057CrossRef
31.
Zurück zum Zitat Charafe-Jauffret E, Ginestier C, Iovino F, Wicinski J, Cervera N, Finetti P, Hur MH, Diebel ME, Monville F, Dutcher J, Brown M, Viens P, Xerri L, Bertucci F, Stassi G, Dontu G, Birnbaum D, Wicha MS (2009) Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res 69:1302–1313CrossRefPubMed Charafe-Jauffret E, Ginestier C, Iovino F, Wicinski J, Cervera N, Finetti P, Hur MH, Diebel ME, Monville F, Dutcher J, Brown M, Viens P, Xerri L, Bertucci F, Stassi G, Dontu G, Birnbaum D, Wicha MS (2009) Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res 69:1302–1313CrossRefPubMed
32.
Zurück zum Zitat Sarrio D, Rodriguez-Pinilla SM, Hardisson D, Cano A, Moreno-Bueno G, Palacios J (2008) Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype. Cancer Res 68:989–997CrossRefPubMed Sarrio D, Rodriguez-Pinilla SM, Hardisson D, Cano A, Moreno-Bueno G, Palacios J (2008) Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype. Cancer Res 68:989–997CrossRefPubMed
33.
Zurück zum Zitat Press MF, Finn RS, Di Leo A, Cameron DA, Geyer CE, Martin A, Newstat B, Arbushites M, Koehler M (2008) Correlation of HER2 gene amplification, HER2 and EGFR expression (protein and mRNA) with lapatinib efficacy in women with metastatic breast cancer. J Clin Oncol 26:42SCrossRef Press MF, Finn RS, Di Leo A, Cameron DA, Geyer CE, Martin A, Newstat B, Arbushites M, Koehler M (2008) Correlation of HER2 gene amplification, HER2 and EGFR expression (protein and mRNA) with lapatinib efficacy in women with metastatic breast cancer. J Clin Oncol 26:42SCrossRef
34.
Zurück zum Zitat Resetkova E, Thorat MA, Badve S (2008) Expression of ALDH1 (putative stem cell marker) does not correlate with response to neo-adjuvant chemotherapy (NACT) in breast carcinoma. [Abstracts of the XXVIIth international congress of the international academy of pathology. October 12–17, 2008. Athens, Greece]. Histopathology 53(Abst 133):159 Resetkova E, Thorat MA, Badve S (2008) Expression of ALDH1 (putative stem cell marker) does not correlate with response to neo-adjuvant chemotherapy (NACT) in breast carcinoma. [Abstracts of the XXVIIth international congress of the international academy of pathology. October 12–17, 2008. Athens, Greece]. Histopathology 53(Abst 133):159
35.
Zurück zum Zitat Lim E, Vaillant F, Wu D, Forrest NC, Pal B, Hart AH, Asselin-Labat ML, Gyorki DE, Ward T, Partanen A, Feleppa F, Huschtscha LI, Thorne HJ, Fox SB, Yan M, French JD, Brown MA, Smyth GK, Visvader JE, Lindeman GJ (2009) Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nat Med 15:907–913CrossRefPubMed Lim E, Vaillant F, Wu D, Forrest NC, Pal B, Hart AH, Asselin-Labat ML, Gyorki DE, Ward T, Partanen A, Feleppa F, Huschtscha LI, Thorne HJ, Fox SB, Yan M, French JD, Brown MA, Smyth GK, Visvader JE, Lindeman GJ (2009) Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nat Med 15:907–913CrossRefPubMed
36.
Zurück zum Zitat Yoshida A, Hsu LC, Dave V (1992) Retinal oxidation activity and biological role of human cytosolic aldehyde dehydrogenase. Enzyme 46:239–244PubMed Yoshida A, Hsu LC, Dave V (1992) Retinal oxidation activity and biological role of human cytosolic aldehyde dehydrogenase. Enzyme 46:239–244PubMed
37.
Zurück zum Zitat Yang Q, Sakurai T, Kakudo K (2002) Retinoid, retinoic acid receptor beta and breast cancer. Breast Cancer Res Treat 76:167–173CrossRefPubMed Yang Q, Sakurai T, Kakudo K (2002) Retinoid, retinoic acid receptor beta and breast cancer. Breast Cancer Res Treat 76:167–173CrossRefPubMed
Metadaten
Titel
Prognostic impact of ALDH1 in breast cancer: a story of stem cells and tumor microenvironment
verfasst von
Erika Resetkova
Jorge S. Reis-Filho
Rohit K. Jain
Rutika Mehta
Mangesh A. Thorat
Harikrishna Nakshatri
Sunil Badve
Publikationsdatum
01.08.2010
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 1/2010
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-009-0619-3

Weitere Artikel der Ausgabe 1/2010

Breast Cancer Research and Treatment 1/2010 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.